Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

1.

Genetic features of Lynch syndrome in the Israeli population.

Goldberg Y, Barnes-Kedar I, Lerer I, Halpern N, Plesser M, Hubert A, Kadouri L, Goldshmidt H, Solar I, Strul H, Rosner G, Baris HN, Peretz T, Levi Z, Kariv R.

Clin Genet. 2015 Jun;87(6):549-53. doi: 10.1111/cge.12530. Epub 2014 Nov 28.

PMID:
25430799
2.

Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer.

Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5. doi: 10.1158/1055-9965.EPI-13-0193. Epub 2013 Aug 21.

3.

Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.

Kadouri L, Sagi M, Goldberg Y, Lerer I, Hamburger T, Peretz T.

Breast Cancer Res Treat. 2013 Jul;140(1):207-11. doi: 10.1007/s10549-013-2621-z. Epub 2013 Jul 4.

PMID:
23824362
4.

Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer.

Sonnenblick A, Uziely B, Nechushtan H, Kadouri L, Galun E, Axelrod JH, Katz D, Daum H, Hamburger T, Maly B, Allweis TM, Peretz T.

Breast Cancer Res Treat. 2013 Apr;138(2):407-13. doi: 10.1007/s10549-013-2453-x. Epub 2013 Feb 28.

PMID:
23446809
5.

The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.

Nisman B, Maimon O, Allweis T, Kadouri L, Maly B, Hamburger T, Peretz T.

Anticancer Res. 2013 Jan;33(1):293-9.

PMID:
23267160
6.

Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.

Nisman B, Allweis T, Kadouri L, Mali B, Hamburger T, Baras M, Gronowitz S, Peretz T.

Clin Chem Lab Med. 2013 Feb;51(2):439-47.

PMID:
23093267
7.

Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer.

Sonnenblick A, Rottenberg Y, Kadouri L, Wygoda M, Rivkind A, Vainer GW, Peretz T, Hubert A.

Med Oncol. 2012 Dec;29(5):3035-8. doi: 10.1007/s12032-012-0302-0. Epub 2012 Jul 8.

PMID:
22773040
8.

The clinical effect of the inhibitor of apopotosis protein livin in melanoma.

Lazar I, Perlman R, Lotem M, Peretz T, Ben-Yehuda D, Kadouri L.

Oncology. 2012;82(4):197-204. doi: 10.1159/000334234. Epub 2012 Mar 22.

PMID:
22441029
9.

HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.

Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, Frankenburg S, Machlenkin A, Israel S, Steinberg H, Hamburger T, Peretz T.

Tissue Antigens. 2011 Sep;78(3):203-7. doi: 10.1111/j.1399-0039.2011.01709.x. Epub 2011 Jun 7.

PMID:
21644933
10.

Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.

Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, Hubert A.

Cancer Biol Ther. 2011 Aug 1;12(3):165-8. Epub 2011 Aug 1.

PMID:
21613821
11.
12.

The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin.

Lazar I, Yaacov B, Shiloach T, Eliahoo E, Kadouri L, Lotem M, Perlman R, Zakay-Rones Z, Panet A, Ben-Yehuda D.

J Virol. 2010 Jan;84(1):639-46. doi: 10.1128/JVI.00401-09. Epub .

13.

Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.

Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, Peretz T.

Clin Cancer Res. 2009 Aug 1;15(15):4968-77. doi: 10.1158/1078-0432.CCR-08-3320. Epub 2009 Jul 14.

14.

Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.

Nechushtan H, Hamburger T, Mendelson S, Kadouri L, Sharon N, Pikarsky E, Peretz T.

BMC Cancer. 2009 Feb 18;9:60. doi: 10.1186/1471-2407-9-60.

15.

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.

Hubert A, Mali B, Hamburger T, Rottenberg Y, Uziely B, Peretz T, Kadouri L.

Fam Cancer. 2009;8(3):173-7. doi: 10.1007/s10689-008-9223-7. Epub 2008 Nov 19.

PMID:
19016350
16.

Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin.

Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, Lotem M.

Fam Cancer. 2009;8(1):29-32. doi: 10.1007/s10689-008-9206-8. Epub 2008 Aug 5.

PMID:
18679827
17.

Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers.

Kadouri L, Kote-Jarai Z, Hubert A, Baras M, Abeliovich D, Hamburger T, Peretz T, Eeles RA.

Br J Cancer. 2008 Jun 17;98(12):2006-10. doi: 10.1038/sj.bjc.6604394. Epub 2008 May 27.

18.

Mutation spectrum in HNPCC in the Israeli population.

Goldberg Y, Porat RM, Kedar I, Shochat C, Sagi M, Eilat A, Mendelson S, Hamburger T, Nissan A, Hubert A, Kadouri L, Pikarski E, Lerer I, Abeliovich D, Bercovich D, Peretz T.

Fam Cancer. 2008;7(4):309-17. doi: 10.1007/s10689-008-9191-y. Epub 2008 Apr 4.

PMID:
18389388
19.

Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.

Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D, Peretz T.

J Med Genet. 2007 Jul;44(7):467-71. Epub 2007 Feb 16.

20.

A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer.

Kadouri L, Bercovich D, Elimelech A, Lerer I, Sagi M, Glusman G, Shochat C, Korem S, Hamburger T, Nissan A, Abu-Halaf N, Badrriyah M, Abeliovich D, Peretz T.

BMC Cancer. 2007 Jan 18;7:14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk